![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/ASTEC.png)
Share the post "Astec LifeSciences ‘s Q3 2024-25 Latest News: Revenue Grows by 84.78% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 84.78 % in the past year, decrease in net sales/revenue by -4.76 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 110.67 %. Marginal decrease of -4.2% in other income during this quarter. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Astec LifeSciences Limited. Notable increase of 65.95 % in net profit Year to Year, Astec LifeSciences Limited’s profitability increased by 4.72 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 65.91 % Year to Year. EPS increased by 4.73 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 50.795 Cr | Rs. 98.546 Cr | Rs. 93.858 Cr | -4.76 % | + 84.78 % |
| Expenses | Rs. 69.12 Cr | Rs. 118.28 Cr | Rs. 99.6 Cr | -15.79 % | + 44.1 % |
| Operating Profit | Rs. -18.33 Cr | Rs. -19.73 Cr | Rs. -5.74 Cr | + 70.91 % | + 68.69 % |
| OPM % | -36.09 % | -20.02 % | -6.12 % | + 13.9 % | + 29.97 % |
| Other Income | Rs. 0.909 Cr | Rs. 1.999 Cr | Rs. 1.915 Cr | -4.2 % | + 110.67 % |
| Interest | Rs. 6.1 Cr | Rs. 9.34 Cr | Rs. 9.92 Cr | + 6.21 % | + 62.62 % |
| Depreciation | Rs. 8.7 Cr | Rs. 11.47 Cr | Rs. 11.4 Cr | -0.61 % | + 31.03 % |
| Profit before tax | Rs. -32.22 Cr | Rs. -38.54 Cr | Rs. -25.15 Cr | + 34.74 % | + 21.94 % |
| Tax % | -24.5 % | -0.02 % | -60.52 % | -60.5 % | -36.02 % |
| Net Profit | Rs. -24.33 Cr | Rs. -38.55 Cr | Rs. -40.37 Cr | -4.72 % | -65.93 % |
| EPS in Rs | Rs. -12.41 | Rs. -19.66 | Rs. -20.59 | -4.73 % | -65.91 % |
Today, we’re looking at Astec LifeSciences Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 84.78 %. However, it did see a marginal slip of -4.76 % from the previous quarter. Expenses decreased slightly by -15.79 % quarter-on-quarter, aligning with the annual rise of 44.1 %. Operating profit, while up 68.69 % compared to last year, faced a quarter-on-quarter increase of 70.91 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 29.97 %, but an expansion of 13.9 % sequentially. Other income fell by -4.2 % compared to the last quarter, despite an annual growth of 110.67 %. Interest expenses surged remarkably by 6.21 % from the previous quarter, yet the year-over-year increase remains at a moderate 62.62 %. Depreciation costs fell by -0.61 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 31.03 %. Profit before tax grew annually by 21.94 % but saw an increase from the preceding quarter by 34.74 %.
Tax expenses as a percentage of profits decreased slightly by -36.02 % compared to last year, with a more notable quarter-on-quarter decrease of -60.5 %. Net profit fell by -65.93 % year-on-year but witnessed a -4.72 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -65.91 % but a quarterly fall of -4.73 %. In summary, Astec LifeSciences Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 50.795 Cr | Rs. 98.546 Cr | Rs. 93.858 Cr | -4.76 % | + 84.78 % |
| Expenses | Rs. 69.12 Cr | Rs. 118.28 Cr | Rs. 99.6 Cr | -15.79 % | + 44.1 % |
| Operating Profit | Rs. -18.33 Cr | Rs. -19.73 Cr | Rs. -5.74 Cr | + 70.91 % | + 68.69 % |
| Net Profit | Rs. -24.33 Cr | Rs. -38.55 Cr | Rs. -40.37 Cr | -4.72 % | -65.93 % |
| EPS in Rs | Rs. -12.41 | Rs. -19.66 | Rs. -20.59 | -4.73 % | -65.91 % |
In reviewing Astec LifeSciences Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 84.78 % year-on-year growth, although there was a slight dip of -4.76 % from the previous quarter. Expenses rose by 44.1 % compared to the previous year, with a decrease of -15.79 % quarter-on-quarter. Operating Profit surged by 68.69 % annually, and saw a 70.91 % increase from the last quarter.
Net Profit showed yearly decrease of -65.93 %, and experienced a -4.72 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -65.91 % annually, however dipped by -4.73 % compared to the last quarter. In essence, while Astec LifeSciences Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/HINDUNILVR.png)
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/KUANTUM.png)